Cargando…

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China

BACKGROUND: Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity. Compared with standard chemotherapy in combination with bevacizumab, first‐line c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Guangjian, Yang, Yaning, Liu, Runze, Li, Weihua, Xu, Haiyan, Hao, Xuezhi, Li, Junling, Zhang, Shuyang, Xu, Fei, Lei, Siyu, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844624/ https://www.ncbi.nlm.nih.gov/pubmed/35608132 http://dx.doi.org/10.1002/cam4.4852

Ejemplares similares

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
por: Xu, Haiyan, et al.
Publicado: (2021)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
por: Xu, Haiyan, et al.
Publicado: (2022)

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
por: Yang, Yaning, et al.
Publicado: (2023)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
por: Nong, Jingying, et al.
Publicado: (2021)

Not All EGFR Exon 20 Insertions Are Created Equal
por: Lin, Yen-Ting, et al.
Publicado: (2020)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Wang, Fenfang, et al.
Publicado: (2020)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
por: Tamirat, Mahlet Z., et al.
Publicado: (2021)

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
por: Pacini, Laura, et al.
Publicado: (2022)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yang, Yaning, et al.
Publicado: (2021)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
por: Pacini, Laura, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
por: Zheng, Yue, et al.
Publicado: (2023)

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance
por: Xu, Haiyan, et al.
Publicado: (2019)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
por: Qin, YanRu, et al.
Publicado: (2020)

EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
por: Yudong, Su, et al.
Publicado: (2018)

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
por: Wang, Mengzhao, et al.
Publicado: (2022)

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Vyse, Simon, et al.
Publicado: (2019)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
por: Zhang, Mai, et al.
Publicado: (2023)

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
por: Xu, Chun-Wei, et al.
Publicado: (2020)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
por: Kobayashi, Ikei S., et al.
Publicado: (2021)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
por: Low, Jia Li, et al.
Publicado: (2023)

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2023)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1h0562fq48f7qo1fiteb4mt0s8